SURMOUNT-1 of Eli Lilly is called the experimental test of a combination that will reduce body weight of the people and combat obesity and diseases such as diabetes.
The participants who took tirzepatide they lost up to 52 lbs. (24 kg) in this 72-week phase 3 study. 63% of participants taking tirzepatide 15 mg achieved at least a 20% reduction in body weight as a key secondary endpoint.
This study included 2,539 participants and was the first phase 3 global registration trial evaluating the efficacy and safety of tirzepatide in overweight or obese adults with at least one comorbidity, who do not have diabetes. Tirzepatide met the two co-primary endpoints of greater mean percent change in body weight from baseline and a greater percentage of participants achieving body weight reductions of at least 5% compared to placebo for both.
The main conclusions were given by Louis J. Aronne, director of the Comprehensive Center for Weight Management and the Sanford I. Weill Professor of Metabolic Research at Weill Cornell Medical, an obesity expert at NewYork-Presbyterian/Weill Cornell Medical Center and an investigator for SURMOUNT- one.
“Obesity is a chronic disease that often does not receive the same standard of care as other conditions, despite its impact on physical, psychological and metabolic health, which can include increased risk of hypertension, heart disease, cancer and decreased of survival. Tirzepatide delivered impressive body weight reductions in SURMOUNT-1, which could represent an important step forward in helping the patient-physician association treat this complex disease.”
Participants who had prediabetes at the start of the study will remain enrolled in SURMOUNT-1 for an additional 104 weeks of treatment after the initial 72-week end date to assess the impact on body weight and potential differences in progression to type 2 diabetes. at three years of treatment with tirzepatide compared with placebo.
“Tirzepatide is the first investigational drug to offer more than 20 percent weight loss on average in a Phase 3 study, reinforcing our confidence in its potential to help people living with obesity,” said Jeff Emmick. , MD, Ph.D., Lilly’s vice president of product development.